QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

KYMR

QT52Kymera Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
90.43
+0.53+0.59%
OverviewShort InterestFilings
KYMRQT52Kymera Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
90.43+0.59%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.58
Insider Own31.15%
Shs Outstand82.26M
Perf Week9.00%
Market Cap7.39BForward P/E-EPS next Y-4.27Insider Trans0.24%Shs Float-Perf Month15.73%
Enterprise Value7.33BPEG1.87EPS next Q-0.68Inst Own-Short Float-Perf Quarter13.65%
Income-265478962.00P/S143.69EPS this Y3.34%Inst Trans-Short Ratio-Perf Half Y7.41%
Sales51.46MP/B5.70EPS next Y-23.51%ROA-18.88%Short Interest-Perf YTD16.22%
Book/sh18.72P/C-EPS next 5Y-ROE-25.02%52W High103.00 -12.20%Perf Year95.10%
Cash/sh7.91P/FCF-EPS past 3/5Y-ROIC-22.17%52W Low36.65 146.74%Perf 3Y-
Dividend Est.-EV/EBITDA-23.95Sales past 3/5Y-6.03% 2.78%Gross Margin100.00%Volatility3.09% 3.07%Perf 5Y-
Dividend TTM-EV/Sales142.45EPS Y/Y TTM-18.46%Oper. Margin-697.81%ATR (14)3.78Perf 10Y-
Dividend Ex-Date-Quick Ratio10.81Sales Y/Y TTM8.51%Profit Margin-612.17%RSI (14)66.98Recom2.08
Dividend Gr. 3/5Y-Current Ratio10.81EPS Q/Q13.41%SMA2012.46%Beta0.92Target Price112.60
Payout0.00%Debt/Eq0.05Sales Q/Q54.55%SMA508.87%Rel Volume2.27Prev Close89.90
Employees208LT Debt/Eq0.04EarningsAug 10SMA20022.95%Avg Volume557.00KPrice90.43
IPO DateAug 21, 2020Option/ShortYes / YesEPS/Sales Surpr.20.22% 325.00%Net Debt/EBITDA0.21Volume1,262,245Change0.59%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-08-26ReiteratedLoop Capital Markets$97
May-06-26InitiatedCanaccordBuy$106
Apr-30-26ReiteratedMorgan StanleyOverweight$123 → $119
Feb-26-26ReiteratedMorgan StanleyOverweight$127 → $123
Feb-26-26ReiteratedRBC CapitalOutperform$103 → $108
Jan-06-26DowngradeWolfe ResearchOutperform → Peer Perform
Dec-16-25ReiteratedRBC CapitalOutperform$70 → $103
Dec-11-25ReiteratedStephens$65 → $110
Dec-11-25ReiteratedMizuho Securities$81 → $120
Dec-09-25ReiteratedTruist Financial$80 → $116
Latest News
Jun-12-26
Jun-12-2607:08AM
Kymera Therapeutics Announces Results From Its Phase 1 Study Of KT-621 In Healthy Japanese Adults Were Shared At The Japanese Dermatological Association Annual Meeting, June 11-14Benzinga
Jun-11-26
Jun-11-2606:49PM
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform PotentialSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue513947
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A000
Gross Profit513947
Selling, General and Administrative Excl. Other726864
Research and Development334317240
Other Operating Expense545
Operating Income-360-349-262
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-44-38-38
Net Income Before Taxes-315-312-224
Income Taxes
000
Consolidated Net Income-315-311-224
Net Income From Continuing Operations-315-312-224
Net Income-315-311-224
EPS (Recurring)-3.58-3.69-2.98
EPS (Basic, Before Extraordinaries)-3.58-3.69-2.98
EPS (Diluted)-3.58-3.69-2.98
EBITDA-305-303-216
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio173.77167.59—
Gross Margin100.00100.00100.00
Operating Margin-705.88-894.87-557.45
Net Margin-617.65-797.44-476.60
Shares Outstanding988475
Market Capitalization8,8626,536—
Operating Lease Expense
———
Insider Trading Volume
$95.00$85.10$75.20$65.30$55.40● Close Price0.00M43.12M86.25M129.37M172.50MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Jacobs Bruce N.Chief Financial OfficerJun 02 '26Option Exercise2.0825,30652,636260,241Jun 03 12:00 AM
Chadwick Jeremy GChief Operating OfficerMay 27 '26Sale81.584,279349,09644,018May 27 12:00 AM
Chadwick Jeremy GChief Operating OfficerMay 26 '26Sale79.3612,9051,024,19448,297May 27 12:00 AM
Esposito PamelaDirectorMay 19 '26Option Exercise31.202,00062,4009,000May 19 12:00 AM
Jacobs Bruce N.Chief Financial OfficerMay 18 '26Option Exercise2.0830,00062,400247,588May 19 12:00 AM
Ridloff ElenaDirectorMay 11 '26Option Exercise31.206,000187,20013,000May 11 12:00 AM
Ridloff ElenaDirectorMay 11 '26Sale87.003,000261,0000May 11 12:00 AM
Mainolfi NelloChief Executive OfficerApr 29 '26Option Exercise2.0860,000124,800696,195Apr 29 12:00 AM
Mainolfi NelloChief Executive OfficerApr 29 '26Sale81.1830,0002,435,377666,195Apr 29 12:00 AM
Chadwick Jeremy GChief Operating OfficerApr 22 '26Option Exercise39.0660023,43461,502Apr 24 12:00 AM
Chadwick Jeremy GChief Operating OfficerApr 22 '26Sale90.0030027,00061,202Apr 24 12:00 AM
Booth BruceDirectorApr 22 '26Sale89.966,000539,7720Apr 24 12:00 AM
Booth BruceDirectorApr 22 '26Option Exercise14.4411,800170,33839,868Apr 24 12:00 AM
Chadwick Jeremy GChief Operating OfficerApr 15 '26Sale90.001,300117,00061,202Apr 16 12:00 AM
Booth BruceDirectorApr 15 '26Option Exercise14.184,40062,3925,641Apr 16 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR